Finance Review Daily is tracking this developing story; additional confirmed specifics had not been verified at the time of publication.
Novartis Phase III trial results for del-desiran from the Avidity acquisition miss primary endpoints in treating myotonic dystrophy type 1.
Finance Review Daily is tracking this development following a report from the original source. Additional confirmed specifics had not been verified at the time of publication.
Sophie covers currency markets and central bank policy across Europe, with a focus on how rate decisions ripple through FX pairs. She has been tracking the ECB's policy path since the start of the current easing cycle.
Plus de Sophie Laurent →
